Ann: Response to Aware Query, page-14

nvm i re-read their analysis and risk and it state:

We see Immunotherapies as the key variable in our valuation over the next 12 months. Should COR-1 (Phase II) and COR-2 (Phase Ib) both achieve positive clinical results in their current trials, and assuming no significant change in the viral shedding rate released with the COR-1 interim results, our valuation rises to 58c/share. With respect to downside risk, should both clinical programs fail, we would ascribe a zero value to Immunotherapies (at least until such time as the two HPV pre-clinical programs enter the clinic), and our valuation would fall to 39c/share.

however, the result is not negative either, so idk should i be bothered to invest here atm or not LOL